Invivyd, Inc. (Nasdaq: IVVD), a pioneering biopharmaceutical company dedicated to safeguarding vulnerable populations from severe viral infectious diseases, has recently made headlines with the announcement of the U.S. Food and Drug Administration (FDA) granting Emergency Use Authorization (EUA) for PEMGARDA (pemivibart). This groundbreaking treatment, formerly known as VYD222, is a half-life extended monoclonal antibody (mAb) […]
WuXi Biologics (“WuXi Bio”), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a strategic partnership with Toregem BioPharma, a biotech startup emerging from Kyoto University. This collaboration is set to accelerate the development of TRG035, a promising monoclonal antibody targeting USAG-1 for the treatment of congenital adentia, commonly known as tooth […]
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive global development and marketing rights for the atopic dermatitis drug, MOR106. This deal, potentially worth up to $1.1 billion, underscores Novartis’ commitment to advancing care in immuno-dermatology. Under the terms […]
